Company press releases
| Tid | Selskap | Tittel | Sektor | Kategori |
|---|---|---|---|---|
| 20 Nov 2024 20:31 CET |
BERGENBIO | BerGenBio Appoints Olav Hellebø as CEO | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 13 Nov 2024 07:00 CET |
BERGENBIO | BerGenBio Third Quarter Results 2024 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 06 Nov 2024 07:00 CET |
BERGENBIO | BerGenBio ASA: Invitation to third quarter 2024 results webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 Oct 2024 21:31 CEST |
BERGENBIO | CEO Martin Olin steps down | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 10 Oct 2024 11:07 CEST |
BERGENBIO | BerGenBio ASA: Minutes from Extraordinary General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 07 Oct 2024 07:00 CEST |
BERGENBIO | BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSCLC Patients | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Sep 2024 15:00 CEST |
BERGENBIO | BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 09 Sep 2024 15:24 CEST |
BERGENBIO | BerGenBio to Present Company Update at H.C. Wainright Annual Global Investment Conference | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 21 Aug 2024 07:00 CEST |
BERGENBIO | BerGenBio Second Quarter Results 2024: Solid clinical and financial progress | 20103010 Biotechnology | Half yearly financial reports and audit reports/limited reviews |
| 20 Aug 2024 07:00 CEST |
BERGENBIO | BerGenBio Collaborates with Tempus to Potentially Accelerate Development in STK11m Non-Small Cell Lung Cancer | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Aug 2024 09:57 CEST |
BERGENBIO | BerGenBio ASA: Registration of share capital reduction | 20103010 Biotechnology | Total number of voting rights and capital |
| 13 Aug 2024 07:00 CEST |
BERGENBIO | BerGenBio ASA: Invitation to second quarter and half year 2024 results webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 29 Jul 2024 07:00 CEST |
BERGENBIO | BerGenBio Announces Selection of 2nd Dose in Phase 2a First Line STK11m Non-Small Lung Cancer Trial | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 26 Jun 2024 17:35 CEST |
BERGENBIO | BerGenBio ASA: Grant of share options | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 03 Jun 2024 18:02 CEST |
BERGENBIO | BerGenBio ASA - Registration of reverse share split | 20103010 Biotechnology | Total number of voting rights and capital |
| 30 May 2024 07:00 CEST |
BERGENBIO | BerGenBio ASA - Ex. reverse share split and change of ISIN today | 20103010 Biotechnology | Ex Date |
| 29 May 2024 07:00 CEST |
BERGENBIO | BerGenBio First Quarter Results 2024: Advancing to the Next Stage of Development | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 May 2024 15:11 CEST |
BERGENBIO | BerGenBio Announces NCI Clinical Collaboration with UT Health San Antonio and Sobi® | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 May 2024 14:00 CEST |
BERGENBIO | BerGenBio ASA - Key information relating to the reverse share split and change of ISIN | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 28 May 2024 10:08 CEST |
BERGENBIO | BerGenBio ASA: New share capital registered | 20103010 Biotechnology | Total number of voting rights and capital |
| 23 May 2024 17:15 CEST |
BERGENBIO | BerGenBio ASA - Minutes from the annual general meeting 2024 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 22 May 2024 07:00 CEST |
BERGENBIO | BerGenBio ASA: Invitation to first quarter 2024 results webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 30 Apr 2024 14:00 CEST |
BERGENBIO | BerGenBio ASA: Notice of Annual General Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 30 Apr 2024 13:00 CEST |
BERGENBIO | BERGENBIO ASA: BOARD APPROVAL OF 2023 ANNUAL FINANCIAL STATEMENT AND ANNUAL REPORT 2023 | 20103010 Biotechnology | Annual financial and audit Reports |
| 25 Apr 2024 12:55 CEST |
BERGENBIO | BerGenBio ASA: New share capital registered | 20103010 Biotechnology | Total number of voting rights and capital |
| 17 Apr 2024 17:10 CEST |
BERGENBIO | BerGenBio ASA: Resolution to increase the share capital for settlement of underwriting commission | 20103010 Biotechnology | Total number of voting rights and capital |
| 17 Apr 2024 09:42 CEST |
BERGENBIO | BerGenBio - Disclosure of shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 17 Apr 2024 08:16 CEST |
BERGENBIO | BerGenBio - Disclosure of large shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 16 Apr 2024 14:15 CEST |
BERGENBIO | BerGenBio ASA: Final results for the last exercise period for warrants issued in connection with rights issue | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 15 Apr 2024 10:58 CEST |
BERGENBIO | BerGenBio ASA: Mandatory notification of trade by primary insiders and close associates | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 15 Apr 2024 07:00 CEST |
BERGENBIO | BerGenBio ASA: Siste dag av den siste utøvelsesperioden for de frittstående tegningsrettene utstedt i forbindelse med fortrinnsrettsemisjonen | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 15 Apr 2024 07:00 CEST |
BERGENBIO | BerGenBio ASA: Last day of the last exercise period for warrants issued in connection with rights issue | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 08 Apr 2024 07:15 CEST |
BERGENBIO | BerGenBio ASA: Last day of trading in warrants | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 08 Apr 2024 07:00 CEST |
BERGENBIO | Mandatory notification of trade by related party to Primary Insiders | 20103010 Biotechnology | Mandatory notification of trade primary insiders |
| 03 Apr 2024 13:22 CEST |
BERGENBIO | BerGenBio ASA: Information about the last exercise period for Warrants issued in connection with rights issue | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 02 Apr 2024 08:50 CEST |
BERGENBIO | BerGenBio ASA: Start av den siste utøvelsesperioden for de frittstående tegningsrettene utstedt i forbindelse med fortrinnsrettsemisjonen | 20103010 Biotechnology | Annen informasjonspliktig regulatorisk informasjon |
| 02 Apr 2024 08:50 CEST |
BERGENBIO | BerGenBio ASA: Commencement of the last exercise period for warrants issued in connection with rights issue | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 02 Apr 2024 07:55 CEST |
BERGENBIO | BerGenBio ASA secures underwriting of NOK 118 million gross proceeds representing minimum 80% exercise of the remaining Warrants, providing funding into 2H 2025 | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 27 Mar 2024 15:59 CET |
BERGENBIO | BerGenBio ASA: Exercise price in the last exercise period for warrants issued in connection with rights issue | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 20 Mar 2024 17:15 CET |
BERGENBIO | BerGenBio Announces Initiation of Phase 2a in First Line Non-Small Lung Cancer Patients with a STK11 mutation | 20103010 Biotechnology | Inside information |
| 04 Mar 2024 07:00 CET |
BERGENBIO | BerGenBio to Participate in Carnegie Nordic Healthcare Seminar | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 19 Feb 2024 17:58 CET |
BERGENBIO | BerGenBio ASA - Approval and publication of a prospectus supplement | 20103010 Biotechnology | Prospectus / admission document |
| 14 Feb 2024 07:00 CET |
BERGENBIO | BerGenBio's Fourth Quarter 2023 Results: Focused Strategy Gathers Momentum | 20103010 Biotechnology | Inside information |
| 14 Feb 2024 07:00 CET |
BERGENBIO | BerGenBios resultater for fjerde kvartal 2023: Fokusert strategi gir momentum | 20103010 Biotechnology | Innsideinformasjon |
| 07 Feb 2024 12:00 CET |
BERGENBIO | BerGenBio Announces New Preclinical Data Indicating Broadened Potential for Bemcentinib to Treat Severe Respiratory Infections | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 06 Feb 2024 07:00 CET |
BERGENBIO | BerGenBio ASA: Invitation to fourth quarter 2023 results webcast | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 05 Jan 2024 17:14 CET |
BERGENBIO | BerGenBio ASA – Disclosure of large shareholding | 20103010 Biotechnology | Major shareholding notifications |
| 15 Dec 2023 16:48 CET |
BERGENBIO | BerGenBio announces closure of EU-SolidAct bemcentinib study arm in hospitalized COVID-19 patients | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 12 Dec 2023 07:00 CET |
BERGENBIO | BerGenBio to Present at DNB Nordic Healthcare Conference | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |
| 11 Dec 2023 07:00 CET |
BERGENBIO | BerGenBio Announces Final Bemcentinib Phase 2 Data in AML and MDS Presented at the 2023 ASH Meeting | 20103010 Biotechnology | Additional regulated information required to be disclosed under the laws of a Member State |